Table 1.

Changes in expression in the transition from hormone-sensitive to hormone-refractory disease

AntibodyHistoscores
No. (%) patients
P
ASPCAIPCIncreaseFallNo change
Phospho-Src Y419
    Cytoplasm45 (18.75-80)70 (40-90)13 (26)3 (6)34 (68)0.035
    Membrane20 (0-60)50 (0-90)14 (28)3 (6)33 (66)0.017
Phospho-Src Y527
    Cytoplasm80 (50-112.5)50 (20-90)6 (12)18 (36)26 (52)0.002
    Membrane50 (20-80)20 (0-70)13 (26)21 (42)16 (32)0.101
Total Src
    Cytoplasm130 (100-180)100 (80-126.25)4 (8)16 (32)30 (60)0.009
    Membrane55 (20-116.25)55 (30-110)10 (20)13 (26)27 (54)0.926
Total Lyn
    Cytoplasm28 (5-70)50 (20-80)17 (34)8 (16)25 (50)0.094
    Membrane38 (10-80)70 (35-95)25 (50)6 (12)19 (38)0.005
Total FGR
    Cytoplasm65 (39-100)50 (30-78)8 (16)15 (30)27 (54)0.104
    Membrane95 (69-112)90 (63-108)8 (16)14 (28)28 (56)0.567
  • NOTE: Protein expression for each antibody including median histoscores and IQRs. Membrane and cytoplasm staining was scored separately and the patients were subdivided into those who had an increase in expression from ASPC to AIPC, decrease, and no change. The difference in staining between ASPC and AIPC samples was assessed by Wilcoxon signed-rank test.